STAAR Surgical Company (STAA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$23.47-0.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · STAA
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 7 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $23 STAA trades at 30× p/e, in line with its 28× p/e peer median — but our blended $26 fair value sits above the price. It's a high-confidence read. Analysts target $19–$40. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $31.00 | — | — | Analyst | high |
| graham number | 12M | $11.14 | — | — | TTM | high |
| Peer P/E | 12M | $8.54 | 18.7 | 0.46 | ntm analyst | high |
| Peer P/S | 12M | $18.64 | 2.9 | 6.33 | TTM | high |
| residual income |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$19.00 – $40.00 (median $31.00) · 9 analysts · as of 2026-08-17
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 2435% over what the business is worth with no growth; closing that gap needs roughly — years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $0.03/sh owner earnings.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $8.53 |
| — |
| — |
| TTM |
| high |
| Own P/E history | 12M | $46.65 | 60.0 | 0.78 | TTM | high |
| triangulated | 12M | $23.92 | 28.3 | 0.85 | Triangulated | high |
| Peer P/E | 3Y | $15.86 | 18.7 | 0.85 | Analyst | medium |
| Peer P/S | 3Y | $23.82 | 2.9 | 8.09 | Analyst | medium |
| Own P/E history | 3Y | $20.49 | 60.0 | 0.34 | Analyst | medium |
| Peer P/E | 5Y | $18.69 | 18.7 | 1.00 | Analyst | high |
| Peer P/S | 5Y | $28.06 | 2.9 | 9.53 | Analyst | high |
| Own P/E history | 5Y | $11.84 | 60.0 | 0.20 | Analyst | high |